These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
217 related articles for article (PubMed ID: 23403032)
1. A genome-wide RNA interference screen identifies new regulators of androgen receptor function in prostate cancer cells. Imberg-Kazdan K; Ha S; Greenfield A; Poultney CS; Bonneau R; Logan SK; Garabedian MJ Genome Res; 2013 Apr; 23(4):581-91. PubMed ID: 23403032 [TBL] [Abstract][Full Text] [Related]
2. Identification of kinases regulating prostate cancer cell growth using an RNAi phenotypic screen. Whitworth H; Bhadel S; Ivey M; Conaway M; Spencer A; Hernan R; Holemon H; Gioeli D PLoS One; 2012; 7(6):e38950. PubMed ID: 22761715 [TBL] [Abstract][Full Text] [Related]
3. MED19 alters AR occupancy and gene expression in prostate cancer cells, driving MAOA expression and growth under low androgen. Weber H; Ruoff R; Garabedian MJ PLoS Genet; 2021 Jan; 17(1):e1008540. PubMed ID: 33513133 [TBL] [Abstract][Full Text] [Related]
4. Simultaneous targeting of androgen receptor (AR) and MAPK-interacting kinases (MNKs) by novel retinamides inhibits growth of human prostate cancer cell lines. Ramamurthy VP; Ramalingam S; Gediya L; Kwegyir-Afful AK; Njar VC Oncotarget; 2015 Feb; 6(5):3195-210. PubMed ID: 25605250 [TBL] [Abstract][Full Text] [Related]
5. Context dependent regulatory patterns of the androgen receptor and androgen receptor target genes. Olsen JR; Azeem W; Hellem MR; Marvyin K; Hua Y; Qu Y; Li L; Lin B; Ke X; Øyan AM; Kalland K BMC Cancer; 2016 Jul; 16():377. PubMed ID: 27378372 [TBL] [Abstract][Full Text] [Related]
6. PPP2R2C loss promotes castration-resistance and is associated with increased prostate cancer-specific mortality. Bluemn EG; Spencer ES; Mecham B; Gordon RR; Coleman I; Lewinshtein D; Mostaghel E; Zhang X; Annis J; Grandori C; Porter C; Nelson PS Mol Cancer Res; 2013 Jun; 11(6):568-78. PubMed ID: 23493267 [TBL] [Abstract][Full Text] [Related]
7. A screen for transcription factor targets of glycogen synthase kinase-3 highlights an inverse correlation of NFκB and androgen receptor signaling in prostate cancer. Campa VM; Baltziskueta E; Bengoa-Vergniory N; Gorroño-Etxebarria I; Wesołowski R; Waxman J; Kypta RM Oncotarget; 2014 Sep; 5(18):8173-87. PubMed ID: 25327559 [TBL] [Abstract][Full Text] [Related]
8. The tumor suppressor ING1b is a novel corepressor for the androgen receptor and induces cellular senescence in prostate cancer cells. Esmaeili M; Jennek S; Ludwig S; Klitzsch A; Kraft F; Melle C; Baniahmad A J Mol Cell Biol; 2016 Jun; 8(3):207-20. PubMed ID: 26993046 [TBL] [Abstract][Full Text] [Related]
9. Peroxiredoxin 2 in the nucleus and cytoplasm distinctly regulates androgen receptor activity in prostate cancer cells. Shiota M; Yokomizo A; Kashiwagi E; Takeuchi A; Fujimoto N; Uchiumi T; Naito S Free Radic Biol Med; 2011 Jul; 51(1):78-87. PubMed ID: 21539911 [TBL] [Abstract][Full Text] [Related]
10. Angiogenin mediates androgen-stimulated prostate cancer growth and enables castration resistance. Li S; Hu MG; Sun Y; Yoshioka N; Ibaragi S; Sheng J; Sun G; Kishimoto K; Hu GF Mol Cancer Res; 2013 Oct; 11(10):1203-14. PubMed ID: 23851444 [TBL] [Abstract][Full Text] [Related]
11. Regulation of androgen receptor transcriptional activity by rapamycin in prostate cancer cell proliferation and survival. Wang Y; Mikhailova M; Bose S; Pan CX; deVere White RW; Ghosh PM Oncogene; 2008 Nov; 27(56):7106-17. PubMed ID: 18776922 [TBL] [Abstract][Full Text] [Related]
12. TACC2 is an androgen-responsive cell cycle regulator promoting androgen-mediated and castration-resistant growth of prostate cancer. Takayama K; Horie-Inoue K; Suzuki T; Urano T; Ikeda K; Fujimura T; Takahashi S; Homma Y; Ouchi Y; Inoue S Mol Endocrinol; 2012 May; 26(5):748-61. PubMed ID: 22456197 [TBL] [Abstract][Full Text] [Related]
13. Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer. Hu R; Lu C; Mostaghel EA; Yegnasubramanian S; Gurel M; Tannahill C; Edwards J; Isaacs WB; Nelson PS; Bluemn E; Plymate SR; Luo J Cancer Res; 2012 Jul; 72(14):3457-62. PubMed ID: 22710436 [TBL] [Abstract][Full Text] [Related]
14. PI3K-AKT-mTOR pathway is dominant over androgen receptor signaling in prostate cancer cells. Kaarbø M; Mikkelsen OL; Malerød L; Qu S; Lobert VH; Akgul G; Halvorsen T; Maelandsmo GM; Saatcioglu F Cell Oncol; 2010; 32(1-2):11-27. PubMed ID: 20203370 [TBL] [Abstract][Full Text] [Related]
15. A regulatory feedback loop between Ca2+/calmodulin-dependent protein kinase kinase 2 (CaMKK2) and the androgen receptor in prostate cancer progression. Karacosta LG; Foster BA; Azabdaftari G; Feliciano DM; Edelman AM J Biol Chem; 2012 Jul; 287(29):24832-43. PubMed ID: 22654108 [TBL] [Abstract][Full Text] [Related]
16. Dynein axonemal heavy chain 8 promotes androgen receptor activity and associates with prostate cancer progression. Wang Y; Ledet RJ; Imberg-Kazdan K; Logan SK; Garabedian MJ Oncotarget; 2016 Aug; 7(31):49268-49280. PubMed ID: 27363033 [TBL] [Abstract][Full Text] [Related]
17. Casein kinase 2 inhibition attenuates androgen receptor function and cell proliferation in prostate cancer cells. Yao K; Youn H; Gao X; Huang B; Zhou F; Li B; Han H Prostate; 2012 Sep; 72(13):1423-30. PubMed ID: 22290244 [TBL] [Abstract][Full Text] [Related]
18. Identification of novel genes that regulate androgen receptor signaling and growth of androgen-deprived prostate cancer cells. Levina E; Ji H; Chen M; Baig M; Oliver D; Ohouo P; Lim CU; Schools G; Carmack S; Ding Y; Broude EV; Roninson IB; Buttyan R; Shtutman M Oncotarget; 2015 May; 6(15):13088-104. PubMed ID: 26036626 [TBL] [Abstract][Full Text] [Related]
19. The E3 ubiquitin ligase Siah2 contributes to castration-resistant prostate cancer by regulation of androgen receptor transcriptional activity. Qi J; Tripathi M; Mishra R; Sahgal N; Fazli L; Ettinger S; Placzek WJ; Claps G; Chung LW; Bowtell D; Gleave M; Bhowmick N; Ronai ZA Cancer Cell; 2013 Mar; 23(3):332-46. PubMed ID: 23518348 [TBL] [Abstract][Full Text] [Related]
20. RhoA as a mediator of clinically relevant androgen action in prostate cancer cells. Schmidt LJ; Duncan K; Yadav N; Regan KM; Verone AR; Lohse CM; Pop EA; Attwood K; Wilding G; Mohler JL; Sebo TJ; Tindall DJ; Heemers HV Mol Endocrinol; 2012 May; 26(5):716-35. PubMed ID: 22456196 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]